Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dermata Therapeutics’ SEC filings can feel like a clinical protocol—dense pages of R&D spend, STAR-1 trial updates, and warrant conversions that determine the company’s runway. If you have ever tried to track a Dermata Therapeutics insider trading Form 4 transactions notice or decipher risk factors buried deep in a 10-K, you know the challenge.
Stock Titan solves that problem. Our AI reads every Dermata Therapeutics quarterly earnings report 10-Q filing, flags new burn-rate figures, and translates biotech jargon into plain English. Need a quick view of Dermata Therapeutics Form 4 insider transactions real-time? You’ll receive instant alerts the moment executives exercise warrants or sell shares. Curious about pipeline timelines? Our platform highlights every 8-K clinical milestone and cross-links to prior disclosures so you can see progress at a glance.
- AI-powered summaries turn the 300-page Dermata Therapeutics annual report 10-K simplified into a two-minute read.
- Form-specific dashboards answer common searches like “Dermata Therapeutics proxy statement executive compensation” and “Dermata Therapeutics earnings report filing analysis.”
- Real-time monitoring surfaces each Dermata Therapeutics 8-K material events explained before the market reacts.
Whether you’re comparing Phase 3 spend quarter-over-quarter, watching Dermata Therapeutics executive stock transactions Form 4, or simply understanding Dermata Therapeutics SEC documents with AI, our coverage keeps you ahead. All filings, every form, updated the moment EDGAR posts—so you can focus on clinical inflection points, not paperwork.
Dermata Therapeutics, Inc. reported unaudited second-quarter financials showing total assets of $6.64 million and cash and cash equivalents of $6.48 million as of June 30, 2025, which the company says will fund operations into the second quarter of 2026. The company recorded a net loss of $4.0 million for the six months ended June 30, 2025, and had an accumulated deficit of $69.7 million. Equity financing activity in early 2025 provided material cash inflows, including net proceeds of approximately $5.7 million from a warrant inducement and approximately $2.2 million from a January 2025 PIPE.
Clinical update: Dermata announced that its XYNGARI(TM) Phase 3 STAR-1 trial met all co-primary endpoints at week 12, with inflammatory lesion reductions of -16.8 versus -13.1 for placebo, noninflammatory lesion reductions of -17.3 versus -12.4 for placebo, and IGA responder rates of 29.4% versus 15.2% for placebo. Management notes a second Phase 3 trial (STAR-2) is required by the FDA. The company also discloses supply concentration risk (a Russian supplier) and Nasdaq minimum bid non-compliance with an exception period granted through August 14, 2025, creating ongoing listing risk.
On August 13, 2025 Dermata Therapeutics, Inc. submitted a Current Report on Form 8-K to furnish a press release that provides a corporate update and reports second quarter 2025 financial results for the quarter ended June 30, 2025. The filing identifies the press release as Exhibit 99.1 and an Interactive XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not "filed," and therefore is not subject to Section 18 liability or automatically incorporated by reference into future filings. The report is signed by CEO Gerald T. Proehl.
FAQ
What is the current stock price of Dermata Therapeutics (DRMAW)?
